Drugs / Napabucasin
Napabucasin
also known as
BBI608 · 2-acetylfuranonaphthoquinone · 2-acetylfuro-1,4-naphthoquinone · GB201 · Napabucasina · Napabucasine
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT04299880 | Feb 2020 → May 2021 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03525405 | May → Jun 2018 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03411122 | Jun 2017 → Jan 2018 | — | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02641873 | Dec 2015 → Dec 2016 | colorectal cancer | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02467361 | Aug 2015 → Jan 2021 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02352558 | May 2015 → Dec 2018 | hematopoietic and lymphoid system neoplasm | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02432326 | Apr 2015 → Dec 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02358395 | Feb 2015 → Nov 2017 | hepatocellular carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02231723 | Aug 2014 → Jun 2020 | pancreatic adenocarcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01775423 | Mar 2009 → Aug 2015 | cancer of unknown primary site | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT02851004 | Oct 2016 → Feb 2020 | colorectal cancer | Takayuki Yoshino | Terminated | No outcome recorded |
| Phase 1/2 | NCT02315534 | Mar 2015 → Oct 2018 | glioblastoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02347917 | Feb 2015 → May 2018 | malignant pleural mesothelioma, non-small cell lung carcinoma | Sumitomo Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT02279719 | Dec 2014 → Jul 2019 | hepatocellular carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02024607 | Jan 2014 → Mar 2019 | digestive system cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01325441 | Apr 2011 → Jun 2021 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03647839 | Sep 2018 → Jan 2021 | colorectal cancer | Australasian Gastro-Intestinal Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01776307 | Mar 2012 → Jun 2018 | colorectal cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03721744 | Oct 2018 → Mar 2025 | malignant pancreatic neoplasm | 1Globe Health Institute LLC | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT03522649 | Apr 2018 → Nov 2021 | — | 1Globe Health Institute LLC | Unknown | No outcome recorded |
| Phase 3 | NCT02993731 | Dec 2016 → Mar 2020 | pancreatic ductal adenocarcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02826161 | Nov 2016 → Apr 2017 | non-small cell lung carcinoma | Sumitomo Pharma America, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02753127 | Jun 2016 → Apr 2020 | colorectal cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02178956 | Oct 2014 → Sep 2017 | gastric cancer, gastroesophageal junction adenocarcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01830621 Comparator | May 2013 → May 2016 | colorectal carcinoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Napabucasin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02993731 ↗ |
| Known as | 2-acetylfuranonaphthoquinone | ChEMBL registry synonym — accepted as the source's own label CHEMBL64130 ↗ |
| Known as | 2-acetylfuro-1,4-naphthoquinone | ChEMBL registry synonym — accepted as the source's own label CHEMBL64130 ↗ |
| Known as | BBI608 | “BBI-608 will be supplied free of charge by Boston Biomedical as capsules.” NCT03647839 ↗ |
| Known as | GB201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03721744 ↗ |
| Known as | Napabucasina | ChEMBL registry synonym — accepted as the source's own label CHEMBL64130 ↗ |
| Known as | Napabucasine | ChEMBL registry synonym — accepted as the source's own label CHEMBL64130 ↗ |
| Action | Inhibit | “cancer stem cell pathway inhibitor napabucasin” NCT02753127 ↗ |
| Modality | Small molecule | — CHEMBL64130 ↗ |
| Route | Oral | “Patients will receive BBI608 orally continuously at 200mg BID.” NCT01325441 ↗ |